Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

September 23, 2022

China’s NMPA approves AstraZeneca and Merck’s Lynparza for ovarian cancer

China’s National Medical Products Administration (NMPA) has approved AstraZeneca and Merck’s (known as MSD outside of the US and Canada) Lynparza (olaparib) as maintenance therapy for a type of ovarian cancer.

China’s NMPA approves AstraZeneca and Merck’s Lynparza for ovarian cancer